Global Insulin Pen Market Report 2023 to 2028, Fueled by Growing Diabetic Population - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Insulin Pen Market 2023-2028" report has been added to ResearchAndMarkets.com's offering.

The global insulin pen market is projected to achieve a significant milestone, reaching a value of US$ 73.39 Billion by 2028, with a steady compound annual growth rate (CAGR) of 5.25%. In 2022, the global smart insulin pens market achieved a total market size of US$ 53.98 Billion.

The advancements in diabetes management technologies have brought about positive changes in patient adherence, monitoring, and techniques. One such example is the insulin pen, which offers distinct advantages over traditional vials and syringes. It enables more precise dosing, improved patient compliance, reduced injection site discomfort, and increased patient satisfaction. By using Human Insulin, diabetes patients can mitigate the risk of lifestyle-related complications like cardiovascular diseases.

The growing diabetic population is expected to drive the global insulin pens market, while increased government spending on diabetes aims to introduce innovative therapies and technologies to address the rising prevalence of the condition worldwide. According to the International Diabetes Federation 2021, by 2030, it is estimated that the global diabetic population will reach 643 million individuals, and this number is expected to further escalate to 783 million by 2045.

The increasing use of connected medical devices worldwide has resulted in a significant adoption of insulin pens, driving market growth. The integration of glucose monitoring devices and therapeutics for effective diabetes management is a prominent trend that positively influences the market.

In February 2023, Glooko, a U.S. software company, partnered with Sanofi, a French pharmaceutical company, to integrate SoloSmart with the Glooko platform. SoloSmart is a connected device that works with SoloStar and DoubleStar insulin injection pens. It records insulin dosage, injection details, and enables data visualization in the Glooko app. This collaboration enhances connected care in diabetes management by allowing patients to share their information with healthcare professionals.

The growing prevalence of diabetes, encompassing both type 1 and type 2 cases, has led to a surge in the demand for smart insulin pens globally, fostering market expansion. Improved diagnostics have contributed to a larger population receiving diabetes diagnoses and prescriptions for Human Insulin. The simplicity and accuracy of these pens have boosted their popularity among individuals. The increasing prevalence of diabetes necessitates awareness of type 1 and type 2 disorders.

Disposable insulin pens have emerged as the dominant segment in the global insulin pen market, owing to their convenience and user-friendly design.

By Types, the global smart insulin pens market is segmented into Disposable, Reusable, Smart and Insulin Pen Needle. The disposable insulin pen segment holds a prominent position in the global market, with the highest market share among types. These convenient and user-friendly devices have gained immense popularity among individuals managing diabetes. Disposable pens offer the advantage of simplicity, as they come pre-filled with insulin and eliminate the need for manual filling or cartridge changes. Their compact size and disposable nature make them ideal for on-the-go use and ensure proper dosing accuracy.

With the increasing prevalence of diabetes worldwide, the disposable market is poised for continued growth, catering to the needs of patients seeking a convenient and efficient method of insulin delivery. With the expanding diabetes population, the insulin pen needles market is likely to expand at a rapid pace throughout the forecast period.

Insulin Pen Market Size in China Witnesses Continuous Year-on-Year Growth

By Country, the global smart insulin pens market is divided into the United States, India, China, Brazil, Saudi Arabia, the United Kingdom, Germany, the Netherlands, Sweden, Switzerland, and Australia. The smart insulin pen industry in China has witnessed remarkable growth in recent years. With the increasing prevalence of diabetes and the growing demand for more convenient and accurate insulin delivery methods, insulin pens have gained significant popularity among patients.

The Chinese market is witnessing the entry of both domestic and international players, leading to a competitive landscape. The government's initiatives to improve diabetes management and enhance healthcare infrastructure have also contributed to the growth of the industry.

Germany to Experience Rapid Growth in the Insulin Pen Industry in Upcoming Years

Germany will experience rapid growth in the insulin pen industry in the upcoming years. The country's well-developed healthcare system, high prevalence of diabetes, and focus on patient-centric care have contributed to the increasing demand. German patients are increasingly adopting Human insulin due to its ease of use, accurate dosing, and improved convenience compared to traditional insulin delivery methods.

Companies Mentioned:

1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Becton, Dickinson(BD)
4. Novo Nordisk A/S
5. Ypsomed AG
6. Terumo Corporation

Key Attributes:

For more information about this report visit https://www.researchandmarkets.com/r/puuk18

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900